Image For Activity Cover
The Lead Episode 27: A Discussion of Utility and Limitations of Ablation Index for Guiding Therapy in Ventricular Myocardium
The Ablation Index (AI) has limited value for guiding ablation in ventricular myocardium, particularly scar. This may be related to small proportional significance of application duration and complex tissue architecture.
Learning Objectives
  • To understand the utility and limitations of ablation index for guiding ablation therapy in ventricular myocardium.
Article Authors and Podcast Contributors
Article Authors
Arwa Younis, MD, Israel Zilberman, DVM, Hagai Yavin, MD, Koji Higuchi, MD, Michael Barkagan, MD, Elad Anter, MD

Podcast Contributors
Joshua D. Moss, MD, FHRS, of University of California, San Francisco
Thomas A Dewland, MD, FHRS, of University of California, San Francisco
Nathaniel Steiger, MD, of Brigham and Women's Hospital

Disclosure Policy

ACE Disclosure Policy

The Heart Rhythm Society is committed to the provision of Accredited Continuing Education (formerly known as Continuing Medical Education (CME)) that is balanced, objective, and evidence based. HRS adheres to the Standards for Integrity and Independence in Accredited Continuing Education of the Accreditation Council for Continuing Medical Education (ACCME) which require that those individuals in a position to control the content of an educational activity (including, but not limited to, planners, faculty, authors, committee members, content reviewers, editors, and staff) disclose all financial relationships with an ACCME-defined ineligible company* within the 24 months prior to the disclosure.


Any individual who refuses to disclose financial relationships is disqualified from participating in HRS ACE-certified activities. Owners and employees of ACCME-defined ineligible companies may have no role in the planning or implementation of ACE activities without a special written exemption from the HRS Chief Learning Officer that will be granted only in specific circumstances that meet ACCME requirements.

ACCME Definition:

*An ineligible company is one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Examples of such organizations include:

  • Advertising, marketing, or communication firms whose clients are ineligible companies
  • Bio-medical startups that have begun a governmental regulatory approval process
  • Compounding pharmacies that manufacture proprietary compounds
  • Device manufacturers or distributors
  • Diagnostic labs that sell proprietary products
  • Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
  • Manufacturers of health-related wearable products
  • Pharmaceutical companies or distributors
  • Pharmacy benefit managers
  • Reagent manufacturers or sellers


All relevant financial relationships have been mitigated.

Host Disclosure(s):
J. Moss: Honoraria/Speaking/Consulting Fee: Biosense Webster, Farapulse, Haemonetics, Baylis Medical, Abbott; Stocks (Publicly Traded): Doximity, Moderna Therapeutics

Contributor Disclosure(s):
T. Dewland: Honoraria/Speaking/Consulting Fee: Adagio Medical
N. Steiger: No relevant financial relationships with ineligible companies to disclose. 

Staff Disclosure(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner):
J. Glenn: No relevant financial relationships with ineligible companies to disclose. 
S. Sailor: No relevant financial relationships with ineligible companies to disclose.
Availability: On-Demand
Cost: FREE
Credit Offered:
No Credit Offered
  Heart Rhythm Society
1325 G Street NW, Suite 500
Washington, DC 20005
P: 202-464-3400 F: 202-464-3401
© Heart Rhythm Society
Privacy Policy | Linking Policy | Patient Education Disclaimer | State Nonprofit Disclosures | FAQ
Android App Download IOS App Download Powered By